The EU is to fund a 14-member group of biotech companies and clinical centers in Europe and the U.S. in an effort to develop a more sophisticated, personalized, approach to the development of cancer vaccines.
The 28-nation bloc is providing €6 million ($7.7 million) through the EU's Framework-7 grant program for the Glioma Actively Personalized...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?